

Primary Care Asthma & COPD Program

Finalized Minimum Data Set (MDS) for the Quality Review Process (QRP)

Indicator	Definition/Values
Percentage of individuals aged 6 years or older clinically suspected* of having asthma who complete spirometry to confirm diagnosis with a PCAP CRE.	• <u>Numerator</u>: Number of individuals in the denominator whose diagnosis was confirmed with spirometry (with or without bronchodilator reversibility testing). • <u>Denominator</u>: Total number of individuals aged 6 years and older clinically suspected of having asthma and seen by a PCAP CRE.
Percentage of individuals with asthma who had an emergency department visit, urgent care centre visit*, or hospitalization for an asthma-specific reason while being managed by PCAP* in the last year.	• <u>Numerator</u>: Number of individuals in the denominator who had at least one emergency department visit, urgent care centre visit*, or hospitalization for asthma in the previous year while being managed by PCAP. • <u>Denominator</u>: Number of individuals diagnosed with asthma in the last year managed by PCAP.

Percentage of individuals clinically suspected of having COPD who complete spirometry to confirm diagnosis with a PCAP CRE.	• <u>Numerator:</u> Number of individuals in the denominator whose diagnosis was confirmed with spirometry (with or without bronchodilator reversibility testing). • <u>Denominator:</u> Total number of individuals clinically suspected of having COPD and seen by a PCAP CRE.
Percentage of individuals with COPD who had an emergency department visit, urgent care centre visit*, or hospitalization for a COPD-specific reason while being managed by PCAP in the last year.	• <u>Numerator:</u> Number of individuals in the denominator who had at least one emergency department visit, urgent care centre visit, or hospitalization for COPD in the previous year while being managed by PCAP. • <u>Denominator:</u> Number of individuals diagnosed with COPD in the last year managed by PCAP.
Percentage of individuals seen by a PCAP CRE who were asked about their tobacco and/or nicotine use and, if current users, were offered a cessation intervention (e.g., counselling, pharmacotherapy) in the past year.	• <u>Numerator:</u> Number of individuals in the denominator who were asked by a PCAP CRE about their tobacco and/or nicotine use status and, if current users, were offered a cessation intervention (e.g., counselling, pharmacotherapy) in the past year. • <u>Denominator:</u> Total number of individuals seen by a PCAP CRE in the past year.

PCAP MDS: Key Term Definitions & Clarifications

***Clinically suspected:** Refers to individuals identified as potentially having asthma or COPD based on symptoms, clinical history, and/or risk factors, prior to confirmation by objective testing (e.g., spirometry).

***Urgent care centre:** A facility that provides unscheduled, walk-in care for acute but non-life-threatening conditions outside of the primary care system (e.g., a standalone urgent care centre). This does not include same-day or urgent appointments arranged within a patient's own primary care practice.

***Managed by PCAP:** Refers to individuals who are actively enrolled in and receiving care through a PCAP site, including assessment, education, and/or follow-up by program staff (e.g., Certified Respiratory Educators), at the time of measurement.

***Healthcare utilization data** (e.g., EDs/hospitalizations) may be captured via patient self-report.

Acknowledgements

The MDS was developed with guidance from the PCAP Advisory Committee. We gratefully acknowledge committee members for their expert contributions to the development, refinement, and voting process that informed that the indicators presented in this document.

Advisory Committee members include:

- Alan Kaplan, MD, CCFP(EM), FCFP, Family Physician, Chair Family Physician Airways Group of Canada
- Andrew Kouri, MD, PhD, FRCPC, Adult Respiriologist, Women's College Hospital, Division of Respiriology
- Connie Yang, MD, MSc, Pediatric Respiriologist, Associate Professor, SickKids Hospital, University of Toronto
- Delanya Podgers, RN(EC), MN, CRE, Nurse Practitioner and Clinical Lead Asthma & COPD, Kingston Health Sciences Centre
- Gracia Mabaya, MSc, MPH, PhD(c), Manager, Clinical and Quality Standards Program, Ontario Health
- Mika Nonoyama, RRT, PhD, Respiratory Therapist, Associate Professor, Faculty of Health Sciences, Ontario Tech University
- Shirley Quach, RRT, CRE PhD, Director, Person-Centered Care & Programs, Lung Health Foundation

References

- Chen, P., et al. (2023). Secondhand smoke exposure and the risk of chronic obstructive pulmonary disease: A systematic review and meta-analysis. *International Journal of Chronic Obstructive Pulmonary Disease*, 1067–1076.
- Durber, S. A. (2025). Self-management care plans for patients with severe chronic obstructive pulmonary disease: A quality improvement project. *Primary Health Care*, 35(6).
- Fu, Y., et al. (2022). Evidence-based management approaches for patients with severe chronic obstructive pulmonary disease (COPD): A practice review. *Palliative Medicine*, 36(5), 770–782.
- Gershon, A. S., et al. (2019). Development of quality indicators for chronic obstructive pulmonary disease (COPD): A modified RAND appropriateness method. *Canadian Journal of Respiratory, Critical Care, and Sleep Medicine*, 3(1), 30–38.
- Global Initiative for Chronic Obstructive Lung Disease. (2010). GOLD spirometry guide. <https://goldcopd.org/gold-spirometry-guide/>
- Global Initiative for Chronic Obstructive Lung Disease. (2026). Global strategy for the diagnosis, management, and prevention of COPD: 2026 report.
- Horita, N., Nagashima, A., & Kaneko, T. (2017). Long-acting β -agonists (LABA) combined with long-acting muscarinic antagonists or LABA combined with inhaled corticosteroids for patients with stable COPD. *JAMA*, 318(13), 1274–1275. <https://doi.org/10.1001/jama.2017.11903>
- Kumbhare, S. D., Beiko, T., Wilcox, S. R., & Strange, C. (2016). Characteristics of COPD patients using United States emergency care or hospitalization. *Chronic Obstructive Pulmonary Diseases*, 3(2), 539–548.
- Licskai, C., Hussey, A., Rowley, V., et al. (2024). Quantifying sustained health system benefits of primary care-based integrated disease management for COPD: A 6-year interrupted time series study. *Thorax*, 79, 725–734.
- Lim, E., et al. (2011). Using hospital readmission rates to track the quality of care in public hospitals in Singapore. *BMC Health Services Research*, 11(Suppl 1), A16.

Miravittles, M., Kawayama, T., & Dreher, M. (2022). LABA/LAMA as first-line therapy for COPD: A summary of the evidence and guideline recommendations. *Journal of Clinical Medicine*, 11(22), 6623. <https://doi.org/10.3390/jcm11226623>

National Institute for Health and Care Excellence. (2022). COPD: Annual review [NICE indicator IND191]. <https://www.nice.org.uk/indicators/ind191>

Ontario Health. (2023). Chronic obstructive pulmonary disease: Care in the community for adults [Quality standard].

Shabil, M., et al. (2025). Association of electronic cigarette use and risk of COPD: A systematic review and meta-analysis. *npj Primary Care Respiratory Medicine*, 35(1), 31.

Su, W.-C., et al. (2024). Secondhand smoke increases the risk of developing chronic obstructive pulmonary disease. *Scientific Reports*, 14(1), 7481.

U.S. Preventive Services Task Force. (2021). Interventions for tobacco smoking cessation in adults, including pregnant persons: US Preventive Services Task Force recommendation statement. *JAMA*, 325(3), 265–279. <https://doi.org/10.1001/jama.2020.25019>

Wang, Z., et al. (2024). Effects of smoking cessation on individuals with COPD: A systematic review and meta-analysis. *Frontiers in Public Health*, 12, 1433269.

Williams, P. J., et al. (2024). Impact of omitting annual reviews for COPD on patient reported care quality: Outcomes from the Asthma+Lung COPD patient passport. *BMJ Open*, 14, e080282. <https://doi.org/10.1136/bmjopen-2023-080282>